Rubicon Research IPO: The initial public offering (IPO) of Rubicon Research Limited entered its second day of public bidding today, October 10, with the issue subscribed 74 per cent so far, as per provisional exchange data. The pharmaceutical formulations company aims to raise Rs 1377.50 crore from the public offering of 2.84 crore equity shares.
The issue opened for public subscription on October 9 will remain open till October 13, 2025.
Rubicon Research IPO subscription status:
By 11 am, investors have bid for 1.21 crore shares out of the total shares on offer. Categorically, Qualified Institutional Buyers (QIBs), Non-Institutional Investors (NIIs) and Retail Individual Investors (RIIs) have subscribed 0.26 times, 0.77 times, and 2.12 times against their allotted portions, respectively.
Add Zee Business as a Preferred Source
Read More:Â Canara Robeco IPO Day 2: Issue sees 30% subscription so far with steady retail demand; QIBs lag behind
Rubicon Research IPO details:
The IPO is a book-building issue of Rs 1,377.50 crore, which includes a fresh issue of 1.03 crore equity shares worth Rs 500 crore and an offer for sale (OFS) of 1.80 crore equity shares worth Rs 877.50 crore.
The company has reserved approximately 36,082 equity shares (based on the upper cap) for its eligible employees.
From the rest, the Qualified Institutional Buyers (QIBs) quota has been allotted not less than 75 per cent, while not more than 15 per cent is reserved for High-Net-Worth Individuals (HNIs) and not more than 10 per cent for Retail investors.
The company plans to utilise the proceeds raised for debt repayment, funding inorganic growth and for general corporate purposes.
Price band: Rs 461 to Rs 485 apiece
Face value: Re 1 each
Subscription date: October 9 to October 13, 2025
Lot size: 30 shares
Minimum investment: Rs 14,550 based on the upper end of the price band
Allotment date: October 14, 2025
Listing date: October 16 on BSE and NSE
Rubicon Research company profile:
Rubicon Research Limited is a pharmaceutical formulations company focused on innovation through research and development, with a strong presence in regulated markets, particularly the United States.
They have a portfolio of 66 commercialised products and 72 active ANDAs and NDAs approved by the US FDA.
Financially, the company reported a net profit of Rs. 43.30 crore on a total income of Rs. 356.95 crore in Q1 FY26, which ended on June 30, 2025, from a net profit of Rs. 25.57 crore on a total income of Rs. 321.90 crore for the previous period.
